Quest PharmaTech Inc. (QPTFF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.32 Million CAD | 19.56% |
| 2022 | 1.1 Million CAD | 77.71% |
| 2021 | 622.59 Thousand CAD | 59.87% |
| 2020 | 389.44 Thousand CAD | -96.87% |
| 2019 | 12.44 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.15 Million CAD | -12.86% |
| 2024 Q2 | 1.07 Million CAD | -7.01% |
| 2023 Q1 | 997.36 Thousand CAD | -9.86% |
| 2023 FY | 1.32 Million CAD | 19.56% |
| 2023 Q3 | 1.16 Million CAD | 12.59% |
| 2023 Q4 | 1.32 Million CAD | 13.58% |
| 2023 Q2 | 1.03 Million CAD | 3.72% |
| 2022 Q3 | 1.02 Million CAD | 0.0% |
| 2022 Q4 | 1.1 Million CAD | 8.28% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | 59.293% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.518% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -213.775% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.357% |
| Intellipharmaceutics International Inc. | 12 Million USD | 88.985% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.175% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.759% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 65.655% |
| Marizyme, Inc. | 26.67 Million USD | 95.041% |
| Genus plc | 485 Million USD | 99.727% |
| Pharming Group N.V. | 244.07 Million USD | 99.458% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 34.194% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 47.432% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 65.19% |
| ContraFect Corporation | 32.53 Million USD | 95.934% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 65.442% |
| IMV Inc. | 37.93 Million USD | 96.513% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 88.769% |
| ONE Bio Corp. | 27.49 Million USD | 95.189% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.291% |
| Mesoblast Limited | 188.44 Million USD | 99.298% |
| MultiCell Technologies, Inc. | 1617.67 USD | -81670.509% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.405% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.9% |
| Neon Bloom, Inc. | 1.22 Million USD | -7.875% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 74.295% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 86.195% |
| Biomind Labs Inc. | 1.49 Million USD | 11.733% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 85.371% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 92.812% |
| Skye Bioscience, Inc. | 14.07 Million USD | 90.6% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 7.747% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 77.36% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -830.91% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 33.237% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 86.026% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -557.718% |
| Accustem Sciences Inc. | 1.07 Million USD | -22.566% |
| EV Biologics, Inc. | 2.11 Million USD | 37.459% |
| Q BioMed Inc. | 8.13 Million USD | 83.736% |
| GB Sciences, Inc. | 5.41 Million USD | 75.584% |
| Alpha Cognition Inc. | 7.16 Million USD | 81.538% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Agentix Corp. | 2.51 Million USD | 47.311% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.886% |
| Enzolytics Inc. | 365.26 Million USD | 99.638% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 98.037% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -57.712% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 76.978% |
| argenx SE | 444.95 Million USD | 99.703% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.234% |
| HST Global, Inc. | 593.59 Thousand USD | -122.842% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 22.825% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -5.05% |
| Halberd Corporation | 728.71 Thousand USD | -81.521% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 94.655% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 63.909% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4698.059% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 88.887% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 64.578% |
| AVAX Technologies, Inc. | 3.99 Million USD | 66.879% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -94.288% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 51.219% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -454.266% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 83.172% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1876.388% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.368% |
| Kadimastem Ltd | 3.5 Million USD | 62.259% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 91.683% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -184.652% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4721.846% |
| LadRx Corporation | 2.2 Million USD | 39.888% |
| Cell Source, Inc. | 15.8 Million USD | 91.632% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2859.497% |
| Regen BioPharma, Inc. | 5.45 Million USD | 75.763% |
| Regen BioPharma, Inc. | 5.45 Million USD | 75.763% |
| Affymax, Inc. | 8.87 Million USD | 85.089% |
| Mobile Lads Corp. | 1.31 Million USD | -0.707% |
| Itoco Inc. | 1.65 Million USD | 19.985% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 35.524% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 78.132% |
| International Stem Cell Corporation | 5.27 Million USD | 74.933% |
| CytoDyn Inc. | 127.89 Million USD | 98.966% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3064.614% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 15.552% |
| Qrons Inc. | 1.48 Million USD | 11.146% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 88.024% |
| SYBLEU INC | 681.41 Thousand USD | -94.123% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -63.549% |
| Rebus Holdings, Inc. | 5.24 Million USD | 74.766% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 78.322% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -111.371% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 71.351% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.773% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.059% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 34.69% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 75.853% |
| Neutra Corp. | 973.52 Thousand USD | -35.874% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.441% |
| PureTech Health plc | 125.58 Million USD | 98.947% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 64.793% |
| IXICO plc | 1.9 Million USD | 30.391% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 93.557% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.72% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Cellectis S.A. | 249.36 Million USD | 99.47% |